Asset
Spironolactone
Actinium Pharmaceuticals Inc. (Delaware) Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02575963 | phase1_2 | completed | 2012-10-01 | 2018-11-01 | Actinium Pharmaceuticals | Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients |
| NCT03867682 | phase1_2 | unknown | 2020-01-15 | 2023-11-01 | Actinium Pharmaceuticals | Venetoclax and Lintuzumab-Ac225 in AML Patients |
FDA applications (0)
This company has no applications containing this asset.